Production, purification and analysis of an experimental DNA vaccine against rabies
- 17 August 2001
- journal article
- research article
- Published by Wiley in The Journal of Gene Medicine
- Vol. 3 (6) , 577-584
Abstract
Background The basic and applied research efforts devoted to the development of DNA vaccines must be accompanied by manufacturing processes capable of being scaled up and delivering a clinical‐grade product. This work describes a rapid process of this kind, based on hydrophobic interaction chromatography (HIC) for the production of milligram quantities of an experimental DNA rabies vaccine. Its properties and protective activity are tested in comparison with the same plasmid DNA purified with a commercial kit. Methods The experimental DNA vaccine encoding the rabies virus glycoprotein was amplified in vivo in Escherichia coli. The plasmid was isolated by alkaline lysis, pre‐purified and concentrated by isopropanol and (NH4)2SO4 precipitation, and purified by HIC and dialysis. Product quality was controlled by using high‐performance liquid chromatography (HPLC), Southern slot blotting, agarose gel electrophoresis, the kinetic‐QCL Limulus amoebocyte lysate assay, and protein assays. The expression of the rabies virus glycoprotein was tested in vitro in neuroblastoma cells. The production of rabies‐virus‐neutralising antibodies and the protection against an intracerebral virus challenge were tested in mice. Results One hundred and forty‐two milligrams of the plasmid, with an HPLC purity greater than 99% were obtained from 4.5 l medium. Control analysis showed that the vaccine conforms to specifications in terms of impurities (endotoxins, genomic DNA, RNA, proteins). Furthermore, the final experimental vaccine induces rabies‐virus‐neutralising antibodies and protects mice against a rabies virus challenge. Conclusions This study demonstrates that the method developed for the purification of milligram amounts of plasmid delivers an endotoxin‐free, experimental rabies DNA vaccine, with protective activity similar to that obtained with the vaccine purified using a commercial kit. Copyright © 2001 John Wiley & Sons, Ltd.Keywords
This publication has 14 references indexed in Scilit:
- Scale-up of hydrophobic interaction chromatography for the purification of a DNA vaccine against rabiesBiotechnology Letters, 2000
- Purification of a cystic fibrosis plasmid vector for gene therapy using hydrophobic interaction chromatographyBiotechnology and Bioengineering, 2000
- Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteersVaccine, 2000
- DNA-Based Immunization against LyssavirusesIntervirology, 2000
- Immunization of dogs with a DNA vaccine induces protection against rabies virusVaccine, 1999
- Lyssavirus glycoproteins expressing immunologically potent foreign B cell and cytotoxic T lymphocyte epitopes as prototypes for multivalent vaccinesJournal of General Virology, 1999
- HIV-1 DNA vaccinesImmunology Letters, 1999
- Gene vaccination: plasmid DNA is more than just a blueprintImmunology Today, 1998
- Rationale and Prospects for Rabies Elimination in Developing Countries1994
- Preparation of adsorbents for biospecific affinity chromatographyJournal of Chromatography A, 1974